Skip to main content

Profile: Claire Mach

Claire Mach
Claire M. Mach, Pharm.D.
Clinical Assistant Professor
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Health and Biomedical Sciences Building 2, Room 4037
4849 Calhoun
College of Pharmacy
Houston, TX 77204-5000
832-842-8373
832-842-8383 (Fax)
cmach@uh.edu

Education

  • Doctor of Pharmacy, University of Houston College of Pharmacy, Houston, Texas
  • Oncology Translational Research Fellowship, University of Texas M.D. Anderson Cancer Center, Houston, Texas
  • Bachelor of Science, Biochemistry, Texas A&M University, College Station, Texas

Certifications

  • Pharmacist Preceptor, Texas State Board of Pharmacy
  • ACLS Provider, American Heart Association
  • Anticoagulation Therapy Management Certification, USI Program
  • Pharmacy-Based Immunization Delivery Certification, ACPE/APhA
  • ACPE IV Sterile Products, University of Houston College of Pharmacy

Research Interests

  • Evaluation of tubby-like protein 4 (TULP4) expression and function in uterine leiomyosarcoma
  • High throughput target discovery in uterine papillary serous carcinoma (UPSC)

Awards, Honors & Recognition

  • 2010-11 Gynecologic Cancer Foundation/Carol’s Cause Endometrial Cancer Research Grant
  • Travel Grant Award Recipient, Hematology/Oncology Pharmacy Association, May 2007

Courses

  • PHAR 5280 Therapeutics (Oncology module)
  • PHAR 5679 Women’s Health Therapeutics (elective)
  • PHAR 5680 Oncology (elective)

Selected Publications

Peer-Reviewed Journal Articles

Miller H, Ike C, Parma J, Masand RP, Mach CM, Anderson ML. Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma Sarcoma. 2016;2016:7018106.

Mach CM, Lapp EA, Weddle KJ, Hunter RJ, Burns KA, Parker C, Brown J, Smith JA. Adjunct Histamine Blockers as Premedications to Prevent Carboplatin Hypersensitivity Reactions. Pharmacotherapy. 2016 May;36(5):482-7. doi: 10.1002/phar.1739. Epub 2016 Apr 4.

Anderson ML, Ogunwale A, Clark BA, Kilpatrick CC, Mach CM. Preferences and Outcomes for Chemotherapy Teaching in a Postgraduate Obstetrics and Gynecology Training Program. J Surg Educ. 2015 Sep-Oct;72(5):936-41. doi: 10.1016/j.jsurg.2015.04.008. Epub 2015 Jun 26.

Mach CM, Urh A, Anderson ML. Bowel perforation associated with temsirolimus use in a recently irradiated patient. Am J Health Syst Pharm. 2014 Jun 1;71(11):919-23. doi: 10.2146/ajhp130145.

Kelm J, Magliaro TJ, Anderson ML, Mach CM*. Vismodegib provides a novel treatment for advanced basal cell carcinoma. Journal of Cancer Therapy. 2014; 5:217-221. Doi:10.4236/jct.2014.52027.

Wan Y, Mach CM, Allen GI, Anderson ML, Liu Z. On the reproducibility of TCGA ovarian cancer microRNA profiles. PLOS One. 2014 Jan 29;9(1):e87782. Doi:10.1371/journal.pone.0087782. ecollection 2014.

This paper was highlighted by the editor of Nature Methods as “Research Highlight”: MiRNA profiling depends on platform. Nature Methods 11, 369 (2014) doi:10.1038/nmeth.2905Published online 28 March 2014
http://www.nature.com/nmeth/journal/v11/n4/full/nmeth.2905.html

Francis JC, Kolomeyevskaya N, Mach CM, Dietrich JE, Anderson ML. MicroRNAs and recent insights into pediatric ovarian cancers. Front Oncol. 2013 Apr 30;3:95. PMID 23641362.

Mach CM, Kim J, Soibam B, Creighton CJ, Hawkins SM, Zighelboim I, Goodfellow P, Gunaratne PH, Odunsi K, Salem PA, Anderson ML. Novel microRNAs regulating proliferation and apoptosis in uterine papillary serous carcinomas. Cancer Lett. 2013 Feb 26. pii: S0304-3835(13)00169-9 [Epub ahead of print]. PMID: 23454583

Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA. Evaluation of Liposomal curcumin cytochrome P450 metabolism. Anticancer Research 2010;30:811-814.

Mach CM, Mathew L, Mosely SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer. Anticancer Research 2009;29:1895-1900.

Mach CM, Fujii H, Wakame K, Smith JA. The evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer. Journal of the Society of Integrative Oncology 2008;6:105-9.

Mach CM, Hargrove B, Kunkel G. The small RNA gene activator protein, SphI postoctamer homology-binding factor/selenocysteine tRNA gene transcription activating factor, stimulates transcription of the human interferon regulatory factor-3 gene. Journal of Biological Chemistry 2002;277:4853-4858.

Book Chapters

Ke S, Wang W, Qui X, Zhang F, Anderson ML, Mach CM, Konopleva M, Yustein JT, Zou C, Gao X, Lin J, Sun J, Cameron AG.  Retinoic Acid: An Old Compound with a Potential for Future Use in Personalized Molecular Medicine in: Retinoic Acid:  Structure, Mechanisms and Roles in Disease. Cheng Li-Hong and Ito Yuto (eds). Nova Science Publishers, ebook, 2012.  

Mach CM and Coultier L. Endometrial Cancer in: Women’s Health Across the Lifespan: A Pharmacotherapeutic Approach. Borgelt LM, O’Connell MB, Smith, JA, Calis KA (eds). American Society of Health-System Pharmacists, Inc. Bethesda, MD. Chapter 44. 1st Edition 2010.

Research Projects

Active Projects

OC140269 CM Mach, ML Anderson
Project Role: PI
Source: Department of Defense: Ovarian Cancer Research Program
Title: Assessing a Novel Synthetic Lethal Phenotype Sensitizing Ovarian Cancer to Chemotherapy
Amount Requested: $225,000

CM Mach, ML Anderson
Project Role: PI
Source: AstraZeneca ISSR
Title: Use of miR-520h as a biomarker for response to WEE-1 inhibitors
Amount Requested:  N/A

RP140225 ML Anderson, CM Mach   
Period 9/1/14-8/31/16
Project Role: Co-Investigator
Total Costs: $199,985 (Subcontract to University of Houston: $64,402
Project Role: Co-Investigator
Source: Cancer Prevention and Research Institute of Texas (CPRIT) – High-Impact/High-Risk Award
Title:  Viral MicroRNAs in Ovarian Cancer Growth and Metastasis

Project Goals: 1) Assess the clinical relevance of viral microRNA expression in epithelial ovarian cancer. 2) Dissect the mechanisms by which ebv-miR-BART3 and hcmv-miR-UL112 impact ovarian cancer growth and metastasis in vitro and in vivo.

Completed Projects

CM Mach (PI), "A Micro-RNA Based Strategy for Targeting Uterine Papillary Serous Carcinoma," 2010-11 Gynecologic Cancer Foundation/Carol’s Cause Endometrial Cancer Research Grant, $25,000

Project Goals: 1) Study the function of mir-143 using established UPSC cell lines and xenograft models and dissect the pathways by which altered miR-143 expression promotes UPSC growth and metastasis; 2) Determine whether targeting miR-143 expression increases the effectiveness of chemotherapies currently used to treat this disease.

CM Mach (PI), “Evaluation of tubby-like protein 4 (TULP4) expression and function in uterine leiomyosarcoma,” University of Houston New Faculty Grant, 12/01/09-08/31/10, $6,000

Project Goals: 1) Compare levels of TULP4 expression in ULMS to matched specimens of leiomyoma and myometrium. 2) Assess impact of altered TULP4 expression using novel cell lines.

CM Mach (PI), “Evaluation of drug distrubution in a human ovarian cancer mouse xenograft model,” International Society for Oncology Pharmacy Practice, 06/21/08-7/24/09, $19,000

Project Goals: 1) Compare and contrast the intratumoral pharmacokinetic parameters and total drug exposure in ovarian tumor tissue extracellular fluid of selected taxane and platinum agents administered intraperitoneally and intravenously; 2) Evaluate the differences in systemic response and toxicity profile selected taxane and platinum agents after intraperitoneal chemotherapy administration verses intravenous administration.

Presentations

Invited Talks & Oral Presentations

"ECT2: A Molecular Target for the Treatment of Uterine Papillary Serous Carcinoma (UPSC)," Society of Gynecologic Investigation 61st Annual Scientific Meeting, Florence, Italy, March 26-29, 2014.

"Novel Roles for MicroRNAs as Diagnostic and Therapeutic Targets in Gynecologic Cancers." University of Houston, CSA Clinical Seminar, September 20, 2013.

"Next Generation Sequencing Identifies miR−143 as a Putative Tumor Suppressor in Uterine Papillary Serous Carcinoma." (Abstract O−153 in the final program) Society for Gynecologic Investigation 58th Annual Scientific Meeting, Miami, FL, March 16-19, 2011. (plenary presentation)

"A Unique MicroRNA Locus at 19q13.41 Sensitizes Epithelial Ovarian Cancer to Chemotherapy." Society for Gynecologic Oncology 42nd Annual Meeting, Orlando, FL, March 6-9, 2011. #1049 (plenary presentation March 6, 2011)

"Integrins: New Molecular Targets." ISOPP XII, Prague, Czech Republic, May 5-9, 2010.

"Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer." Society for Integrative Oncology 4th Annual Conference, San Francisco, CA, November 15, 2007.

"Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer." The 15th International Symposium of AHCC Research Association, Sapporo, Japan, July 21-22, 2007.

"Evaluation of the toxicity and tolerability of intraperitoneal chemotherapy for the treatment of ovarian cancer." Platform Presentation at TSHP Alcalde San Antonio, TX, April 20, 2007.

Poster Presentations

(*presenting author)

Mach CM*, Wan Y, Liu Z, Anderson ML. Role of LIN28A/B in Ovarian Cancer Predisposition and Tumorigenicity. AACR 2014 Annual Meeting, San Diego CA. April 5-9, 2014.

Mach CM*, Wan Y, Liu Z, Anderson ML. LIN28B paralogs impact ovarian cancer predisposition and tumorigenicity via distinct molecular pathways. AACR 2013 Annual Meeting, Washington DC. April 6-10, 2013.

Mach CM*, Wan Y, Liu Z, Anderson ML. A bioinformatic approach to defining the role of LIN28 gene products in ovarian cancer. The Cancer Genome Atlas' 2nd Annual Scientific Symposium, Washington DC. November 27-28, 2012.

Stover J, Lee N, McCoy R, Patel P, Hanke J, Mach CM, Anderson ML. Targeting Cervical Cancer Prevention in an Uninsured/Underinsured Patient Population. TSHP Annual Seminar, Dallas, TX, April 12-15, 2012. (poster award)

Mach CM*, Kim J, Anderson ML. Loss of miR-143 promotes the proliferation of UPSC by enhancing exportin-5 expression. Society for Gynecologic Investigation 2012 Annual Scientific Meeting, Austin TX. March 2012.

Mach CM*, Kim J, Soibam B, Creighton CR, Gunaratne PH, Anderson ML. Altered microRNA processing and expression in uterine papillary serous carcinoma. 2011 Innovations in Cancer Prevention and Research Conference, Austin TX, November 15-17, 2011.

Mach CM*, Kim J, Soibam B, Creighton CR, Gunaratne PH, Anderson ML. Genome-wide analysis of small RNA transcripts reveals novel roles of microRNAs and microRNA processing in uterine papillary serous carcinoma. Cell Symposia: Regulatory RNAs, Chicago IL, October 11, 2011.

Mach CM*, Gunaratne P, Anderson ML. A Novel Family of MicroRNAs that Determine Chemosensitivity and Survival for Women with Ovarian Cancer. 2010 Innovations in Cancer Prevention and Research Conference, Austin TX, November 17-19, 2010.

Mach CM*, Kim J, Gunaratne P, Anderson ML. Next Generation Sequencing Identifies miR-143 as a Key MicroRNA Regulating the Proliferation of Uterine Papillary Serous Carcinomas. 8th Annual Dan L. Duncan Cancer Center Symposium. November 11, 2010.

Akinfenwa PY, Kolomeyevskaya NV, Zhen L, Mach CM, Anderson ML. A novel small molecule inhibitor for aurora-A kinase inhibits the growth of cervical cancer in vitro and in vivo. Society for the Study of Reproduction 43rd Annual Meeting, Milwaukee, WI, July 31-August 4, 2010.

Mach CM*, Chen JH, Chee W, Coleman RL, Wolf JK, Markman M, Smith JA. Evaluation of Drug Distribution in an Ovarian Cancer Mouse Xenograft Model. ISOPP XII, Prague, Czech Republic, May 5-9, 2010.

Gunaratne P, Rajib Ghosh R, Mach CM, Creighton CJ, Levine DA, Hayes DN, Wheeler D, Matzuk MM, Anderson ML, Gibbs RA. Identification of novel tumor suppressor microRNAs implicated in epithelial ovarian cancer from the 19q13.41 non-coding RNA cluster. AACR 101st Annual Meeting, Washington DC, April 2010. #2029.

Smith JA, Mathew L, Mach CM*, Santiago K and Helson L.; Development of liposomal curcumin as a new potential anticancer agent. AACR Molecular Cancer Therapeutics (Meeting Abstract Supplement), A29, December 10, 2009.

Mach CM*, Chen JH, Mosley SA, Smith JA. Evaluation of curcumin cytochrome P450 metabolism. HOPA, Miami, FL, June 19, 2009. (poster award).

Mach CM, Mathew L, Mosley SA, Helson L, Kurzrock R, Smith JA. Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Mouse Model of Pancreatic Cancer. ACCP, Louisville, KY, October 20, 2008.

Mach CM*, Jones KL, Wolf JK, Munsell MF, Smith JA. Evaluation of Residual Toxicity and Time to Recurrence Following Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer, HOPA/ISOPP 2008 Conference, June 20, 2008.

Mach CM*, Jones KL, Hunter RJ, Burns KA, Kurian S, Webb NF, Munsell MF, Brown J, Smith JA. Evaluation of the Addition of Premedications Prior to Carboplatin to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients, HOPA/ISOPP 2008 Conference, June 20, 2008.

Mach CM*, Jones KL, Wolf JK, Munsell MF, Smith JA. Evaluation of the Toxicity and Tolerability of Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer, HOPA 3rd Annual Conference, June 15, 2007.

Abstracts

Mach CM. A Micro-RNA Based Strategy for Targeting Uterine Papillary Serous Carcinoma. Society of Gynecologic Oncologists 42nd Annual Meeting on Women’s Cancer, Orlando, FL, March 6, 2011*
*recipient of 2010-11 Gynecologic Cancer Foundation/Carol’s Cause Endometrial Cancer Research Grant

Mach CM, Gunaratne P, Anderson ML. A Novel Family of MicroRNAs that Determine Chemosensitivity and Survival for Women with Ovarian Cancer. 2010 Innovations in Cancer Prevention and Research Conference, Austin, TX, November 17-19, 2010

Akinfenwa PY, Kolomeyevskaya NV, Zhen L, Mach CM, Anderson ML. A novel small molecule inhibitor for aurora-A kinase inhibits the growth of cervical cancer in vitro and in vivo. Society for the Study of Reproduction 43rd Annual Meeting, Milwaukee, WI, July 31-August 4, 2010

Gunaratne P, Rajib Ghosh R, Mach CM, Creighton CJ, Levine DA, Hayes DN, Wheeler D, Matzuk MM, Anderson ML, Gibbs RA. Identification of novel tumor suppressor microRNAs implicated in epithelial ovarian cancer from the 19q13.41 non-coding RNA cluster. AACR 101st Annual Meeting, Washington, D.C., April 2010. #2029

Smith JA, Mathew L, Mach CM, Santiago K and Helson L. Development of liposomal curcumin as a new potential anticancer agent. AACR Molecular Cancer Therapeutics (Meeting Abstract Supplement), A29, December 10, 2009

Mach CM, Chen JH, Mosley SA, Smith JA. Evaluation of curcumin cytochrome P450 metabolism. HOPA, Miami, FL, June 2009

Mach CM, Mathew L, Mosley SA, Helson L, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer. ACCP, Louisville, KY, October 2008

Mach CM, Jones KL, Wolf JK, Munsell MF, Smith JA. Evaluation of residual toxicity and time to recurrence following intraperitoneal chemotherapy for the treatment of ovarian cancer. HOPA/ISOPP 2008 Conference, Anaheim, CA, June 18-21, 2008

Mach CM, Jones KL, Hunter RJ, Burns KA, Kurian S, Webb NF, Munsell MF, Brown J, Smith JA. Evaluation of the Addition of Premedications Prior to Carboplatin to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients. HOPA/ISOPP 2008 Conference, Anaheim, CA, June 18-21, 2008

Mach CM, Fujii H, Wakame K, Smith JA. Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer. Society for Integrative Oncology 4th Annual Conference, San Francisco, CA, November 15, 2007

Mach CM, Fujii H, Wakame K, Smith JA. Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer. The 15th International Symposium of AHCC Research Association, Sapporo, Japan, July 21-22, 2007.

Mach CM, Jones KL, Wolf JK, Munsell MF, Smith JA. Evaluation of the toxicity and tolerability of intraperitoneal chemotherapy for the treatment of ovarian cancer. TSHP Alcalde XXI, San Antonio, TX, April 19-20, 2007. J Oncol Pharm Pract 2007;13:133-158.

Professional Service and Affiliations

Memberships

  • American Association for Cancer Research
  • Hematology/Oncology Pharmacy Association
  • International Society of Oncology Pharmacy Practitioners
  • Texas Society of Health-System Pharmacists

Affiliations

Clinical Pharmacist II, Ben Taub General Hospital, Houston, Texas

Editorial Appointments

  • Editorial Board Member, Journal of Clinical Toxicology, March 2011-present
  • Editorial Board Member, Journal of Clinical Trials, March 2012-present
  • Manuscript Reviewer, PLOS One
  • Manuscript Reviewer, Pharmacotherapy

Other Service Activities

  • Grant Reviewer, DoD OCRP Pilot Award, 2015, 2016
  • Poster Judge, Translational Biology and Molecular Medicine (TBMM) Ph.D. Program 5th Annual Retreat